ArticleJACC. Basic to translational science2017
Technology Transfer: From the Research Bench to Commercialization: Part 2: The Commercialization Process.
Article in JACC. Basic to translational science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Driving emerging technology to clinical impact.Journal of the American Dental Association (1939) · 2026Review
- A framework for developing successful academic-industry partnerships for cardiovascular innovations.Heart rhythm O2 · 2026Review
- Implementation of a digital behavior change intervention (eCHANGE) for weight loss maintenance support: a service design and technology transfer approach.Frontiers in digital health · 2024Article
- Medical Device Development from Ideation to Regulation and Technology Transfer in Low- and Middle-income Countries.Acta medica Philippina · 2023Article
- Access to medicines for rare diseases: A European regulatory roadmap for academia.Frontiers in pharmacology · 2023Article
- Nanotechnology from lab to industry - a look at current trends.Nanoscale advances · 2022Review
- Rules of engagement: Promoting academic-industry partnership in the era of digital pathology and artificial intelligence.Academic pathology · 2022Review
- Challenges and potential solutions for nanosensors intended for use with foods.Nature nanotechnology · 2021Review
- Modular Fabrication of Intelligent Material-Tissue Interfaces for Bioinspired and Biomimetic Devices.Progress in materials science · 2019Article
- How to Start a Biomedical Device Company: Physicians Can Lead the Team Effort.JACC. Basic to translational science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Technology transfer (TT) encompasses a variety of activities that move academic discoveries into the public sector. Part 1 of this 2-part series explored steps in acquisition of intellectual property (IP) rights (e.g., patents and copyrights). Part 2 focuses on processes of commercialization, including the technology transfer office, project development toward commercialization, and licensing either through the establishment of startup companies (venture capital-backed or otherwise) or directly to industry. In private industry, TT often occurs through the sale of IP, products, or services, but in universities, the majority of TT occurs through the licensing of IP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.